Bisphosphonate-associated osteonecrosis of the jaws -- report of three cases in Bulgaria and review of the literature

• Published in: Acta clinica Croatica (Tisak) Vol. 50; no. 2; pp. 273 - 279
• Main Authors: Pechalova, Petia, Bakardjiev, Angel, Zaprianov, Zaprian, Vladimirov, Boyan, Poriazova, Elena, Zheleva, Anastasia, Hadjigeorgiev, Georgi, Goranova-Marinova, Vesselina, Goranov, Stefan
• Format: Journal Article
• Language: English
• Published: Croatia 01.06.2011
• Subjects: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw - pathology; Bisphosphonate-Associated Osteonecrosis of the Jaw - therapy; Bone Density Conservation Agents - adverse effects; Diphosphonates - administration & dosage; Diphosphonates - adverse effects; Female; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Infusions, Intravenous; Male; Middle Aged
• ISSN: 0353-9466

A severe complication of the administration of bisphosphonate-containing medications is known as bisphosphonate-associated osteonecrosis of the jaws (BONJ). A case series of three patients affected by BONJ is presented. These patients currently represent the only described cases of BONJ in Bulgaria. Exposed necrotic bone of the mandible was observed in two patients and the maxilla was affected in the third case. Two of the patients had been treated with zoledronate for metastatic prostate cancer and one patient for metastatic endometrioid cancer. All three patients underwent surgical treatment. One of the patients received conservative surgical debridement, i.e. removal of necrotic bone only, and primary wound closure. Conservative surgical debridement and application of local medications without wound closure were used in the other two patients. All three patients received systemic antibiotic treatment. No evidence of disease progression was observed during the follow-up period of 3 to 12 months. The surgical approach utilized in the present study is discussed in the light of the etiopathogenesis, prevention and treatment of BONJ.